Global Healthcare Investment Report – March 2025: 165 Financing Rounds and $5.324 Billion in Disclosed Funding

According to incomplete statistics from Arterial Intelligence, in March 2025, there were a total of 165 financing events in the global healthcare sector (excluding IPOs, private placements, etc.), with disclosed total financing amounting to approximately $5.324 billion (about 38.193 billion RMB). Among these, 66 financing events occurred in the Chinese market, with a disclosed total financing of about $710 million; overseas markets saw 99 financing events, with a disclosed total financing of approximately $4.614 billion.。

Compared to February 2025, the overall scale of global healthcare industry financing in March 2025 showed an upward trend in terms of transaction value, number of financing events, and focus on emerging fields. The total amount increased by approximately 66.71% month-over-month, and the number of events increased by about 13.01% month-over-month.

In terms of large financing events, there were 12 events exceeding 100 million US dollars this month, with a cumulative financing amount reaching 3.112 billion US dollars. Among them, 10 occurred in overseas regions and 2 took place in China. These 12 companies are: ophthalmic device developer BVI Medical, AI drug developer Isomorphic Labs, German medical professional knowledge platform Amboss, antibody-drug conjugate developer Callio Therapeutics, cardiovascular device developer 4C Medical Technologies, innovative Alzheimer's disease therapy researcher BioClec, non-opioid pain medication developer Latigo Biotherapeutics, global medical technology platform Ruiqiao Dingke, medical auxiliary equipment developer Supira Medical, vaccine developer Curevo, intelligent drug development platform and new drug researcher Insilico Medicine, and hearing aid developer LXE Hearing.

In terms of global medical and health industry sub-sector financing, the medical device and consumables sector and the biopharmaceutical sector have similar overall financing scales, both leading the way; the total financing amount in the medical device and consumables sector reached 2.281 billion US dollars (accounting for 42.83% of the entire field), with 63 events (accounting for 38.18% of the entire field); the total financing amount in the biopharmaceutical sector reached 2.265 billion US dollars (accounting for 42.53% of the entire field), with 55 events (accounting for 33.33% of the entire field). The digital health sector and medical services sector have smaller financing scales, while there are currently no financing events in the pharmaceutical commerce sector.

Notably, BVI Medical, an ophthalmic device developer, completed a $1 billion strategic financing round, securing the top spot for this month's funding. BVI Medical is a diversified ophthalmic surgical device company with a brand portfolio including: Beaver® (scalpels and blades), Visitec® (cannulas), Malosa® (single-use instruments), Vitreq® (vitreoretinal surgery products), and PhysIOL® (advanced intraocular lenses), serving over 90 countries. BVI Medical aims to assist millions of patients suffering from cataracts, refractive errors, glaucoma, retinal diseases, and dry eye syndrome.

On March 31, 2025, AI drug developer Isomorphic Labs announced that it had raised $600 million in its first round of external financing. The round was led by Thrive Capital with participation from GV, and additional funding came from existing investor Alphabet. This investment will accelerate Isomorphic Labs' cutting-edge AI research and development to rapidly advance the company's next-generation AI drug design engine. As a result, Isomorphic Labs will expand its world-class talent team as part of its next phase of growth.

On March 31, 2025, hearing health pioneer Eargo and hearing aid manufacturer hearX announced they have completed their merger, creating a combined company named LXE Hearing. Backed by an additional $100 million investment from Patient Square Capital, the transaction forms a new hearing health company, marking the first significant combination in the over-the-counter (OTC) hearing aid market since the FDA established the regulatory category in 2022.

Medical auxiliary equipment developer Supira Medical completes $120 million oversubscribed Series E financing

On March 26, 2025, Supira Medical, a developer of medical auxiliary equipment, announced the completion of a $120 million oversubscribed Series E financing round. This round was led by Novo Holdings and Qatar Investment Authority, with participation from two undisclosed strategic investors, as well as Cormorant Asset Management, The Capital Partnership (TCP), 415 Capital, AMED Ventures, PA MedTech VC, and Unorthodox Ventures. The proceeds will primarily be used for clinical research on its core product, the Supira pVAD, including high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS).

On March 25, 2025, Ruiqiao Dingke Group announced the completion of its Series A financing round, raising over 1 billion yuan. This round was led by Kangqiao Capital, with participation from Beijing Medical and Health Industry Investment Fund and Beishang Capital. The funds will help Ruiqiao Dingke Group accelerate product development and commercialization efforts, further solidifying its leading position in innovative treatments for high-incidence chronic diseases.

On March 25, 2025, AMBOSS, a German knowledge platform for medical professionals, completed a €240 million financing round, led by KIRKBI, M&G Investments, and Lightrock. The funds will support the expansion into other international markets and broaden its services for nurses and other healthcare professionals.。

Biotechnology Company BioClec Secures €165 Million in Funding to Pioneer Breakthrough Alzheimer's Disease Therapy

On March 18, 2025, biotechnology company BioClec was announced, emerging from Sofinnova Partners' €165 million Biovelocita II accelerator program. BioClec focuses on developing disease-modifying interventions targeting novel microglial pathways in Alzheimer's disease. The company is committed to addressing the unmet and urgent medical needs of AD patients worldwide.。

Vaccine Developer Curevo Raises $110 Million in Series B Funding to Advance Development of Its Shingles Vaccine Amezosvatein

On March 17, 2025, vaccine developer Curevo announced the completion of a $110 million Series B financing round, led by Medicxi with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures, as well as existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma. The Series B funding will support the expansion of Curevo's successful Phase II program, enabling dose selection to be completed for 640 participants, including key populations over 70 years old, prior to the Phase III program.

Non-Opioid Painkiller Developer Latigo Biotherapeutics Completes $150 Million Series B Financing to Advance Non-Opioid Pain Medication Research

On March 17, 2025, Latigo Biotherapeutics, a developer of non-opioid pain relief drugs, completed a $150 million Series B financing round. This round was led by a fund managed by Blue Owl Capital, with participation from Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital. Existing investors Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments also joined this financing round.

Insilico Medicine Completes $110 Million Series E Financing to Accelerate AI and Robotics-Driven Drug Discovery Innovation

On March 13, 2025, Insilico Medicine announced a $110 million Series E financing round led by a private equity fund under Value Partners Group (HKG: 0806), one of Asia's largest independent asset management companies, in collaboration with Pudong Venture Capital, Pudong Development Group, Xichang Venture Capital, and Yixing State-Owned Asset Control. This round of financing also attracted the participation of new investors specializing in industry and technology sectors and received support from existing investors. The proceeds from this financing will be used to drive breakthroughs in Insilico Medicine’s AI platform upgrades and innovation in drug development pipelines. On one hand, the funds will enhance Insilico Medicine's proprietary AI models and algorithms while upgrading and expanding its leading automated robotic laboratories to further achieve and optimize the automation of R&D processes.

Ophthalmic Instrument Developer BVI Medical Secures $1 Billion Strategic Financing to Launch New Products and Expand Business Scale

On March 10, 2025, ophthalmic device developer BVI Medical secured $1 billion in strategic funding from TPG. BVI Medical will use this investment to fund new product launches and expand its operational scale. BVI offers a range of ophthalmic devices, from cryosurgery and cataract surgery systems to intraocular lenses and retinal surgical instruments. The company's main manufacturing plant is located in the United States, but it plans to expand its global footprint based on TPG's substantial investment.。

4C Medical, a cardiovascular device developer, announced the completion of its $175 million Series D financing round, jointly invested by Boston Scientific and HHF Fuyuan.

On March 6, 2025, cardiovascular device developer 4C Medical Technologies, Inc. announced the successful completion of a $175 million Series D financing round. This round was co-led by Boston Scientific and HHF Fuyuan Investment as the only two new investors, with existing shareholders also continuing to increase their investment. The completion of this financing will further accelerate 4C Medical's technology development, clinical progress, and market expansion in the field of heart valve disease treatment. Following multiple rounds of strategic investment support from HeartFlow Medical, 4C Medical has once again successfully gained support from new industry players and professional investment institutions, demonstrating the market's high level of attention and emphasis on the significant potential within the heart valve sector.

Antibody-Drug Conjugate Developer Callio Therapeutics Secures $187 Million in Series A Funding to Develop Next-Generation ADCs

On March 3, 2025, Callio Therapeutics, a developer of antibody-drug conjugates (ADCs), announced the completion of a $187 million Series A financing round. The round was led by Frazier Life Sciences, with strong participation from Jeito Capital and other life science investors including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital, and EDBI. Headquartered in Seattle and Singapore, the newly established company plans to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual payload ADC and a second undisclosed ADC program.

The above is the monthly report overview, more monthly report content is as follows:

Global Biomedical Investment and Financing in March 2025

Global Medical Device Investment and Financing in March 2025

Global Digital Health Investment and Financing in March 2025

Global Healthcare Investment and Financing in March 2025

Welcome ImmediatelyScan the QR code to add the assistantObtainCompleteMonthly ReportAndApply for a Free Trial Database, if added, please inquire proactively: